Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound

AIDS ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Michael J. Corley ◽  
Alina P.S. Pang ◽  
Thomas A. Rasmussen ◽  
Martin Tolstrup ◽  
Ole S. Søgaard ◽  
...  
AIDS ◽  
2014 ◽  
Vol 28 (18) ◽  
pp. 2649-2657 ◽  
Author(s):  
Jonathan Z. Li ◽  
Andrea Heisey ◽  
Hayat Ahmed ◽  
Hongying Wang ◽  
Lu Zheng ◽  
...  

AIDS ◽  
2015 ◽  
pp. 1 ◽  
Author(s):  
Jonathan Z. Li ◽  
Behzad Etemad ◽  
Hayat Ahmed ◽  
Evgenia Aga ◽  
Ronald J. Bosch ◽  
...  

Viruses ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 256 ◽  
Author(s):  
Ekaterina Maidji ◽  
Mary Moreno ◽  
Jose Rivera ◽  
Pheroze Joshi ◽  
Sofiya Galkina ◽  
...  

Although antiretroviral therapy (ART) greatly suppresses HIV replication, lymphoid tissues remain a sanctuary site where the virus may replicate. Tracking the earliest steps of HIV spread from these cellular reservoirs after drug cessation is pivotal for elucidating how infection can be prevented. In this study, we developed an in vivo model of HIV persistence in which viral replication in the lymphoid compartments of humanized mice was inhibited by the HIV reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) to very low levels, which recapitulated ART-suppression in HIV-infected individuals. Using a combination of RNAscope in situ hybridization (ISH) and immunohistochemistry (IHC), we quantitatively investigated the distribution of HIV in the lymphoid tissues of humanized mice during active infection, EFdA suppression, and after drug cessation. The lymphoid compartments of EFdA-suppressed humanized mice harbored very rare transcription/translation-competent HIV reservoirs that enable viral rebound. Our data provided the visualization and direct measurement of the early steps of HIV reservoir expansion within anatomically intact lymphoid tissues soon after EFdA cessation and suggest a strategy to enhance therapeutic approaches aimed at eliminating the HIV reservoir.


2015 ◽  
Vol 90 (3) ◽  
pp. 1369-1376 ◽  
Author(s):  
Mary F. Kearney ◽  
Ann Wiegand ◽  
Wei Shao ◽  
John M. Coffin ◽  
John W. Mellors ◽  
...  

ABSTRACTUnderstanding the origin of HIV variants during viral rebound may provide insight into the composition of the HIV reservoir and has implications for the design of curative interventions. HIV single-genome sequences were obtained from 10 AIDS Clinical Trials Group participants who underwent analytic antiretroviral therapy (ART) interruption (ATI). Rebounding variants were compared with those in pre-ART plasma in all 10 participants and with on-ART peripheral blood mononuclear cell (PBMC)-associated DNA and RNA (CA-RNA) in 7/10 participants. The highest viral diversities were found in the DNA and CA-RNA populations. In 3 of 7 participants, we detected multiple, identical DNA and CA-RNA sequences during suppression on ART that exactly matched plasma HIV sequences. Hypermutated DNA and CA-RNA were detected in four participants, contributing to diversities in these compartments that were higher than in the pre-ART and post-ATI plasma. Shifts in the viral rebound populations could be detected in some participants over the 2- to 3-month observation period. These findings suggest that a source of initial rebound viremia could be populations of infected cells that clonally expanded prior to and/or during ART, some of which were already expressing HIV RNA before treatment was interrupted. These clonally expanding populations of HIV-infected cells may represent an important target for strategies aimed at achieving reservoir reduction and sustained virologic remission.IMPORTANCEAntiretroviral therapy alone cannot eradicate the HIV reservoir, and viral rebound is generally rapid after treatment interruption. It has been suggested that clonal expansion of HIV-infected cells is an important mechanism of HIV reservoir persistence, but the contribution of these clonally proliferating cells to the rebounding virus is unknown. We report a study of AIDS Clinical Trials Group participants who underwent treatment interruption and compared rebounding plasma virus with that found within cells prior to treatment interruption. We found several incidences in which plasma HIV variants exactly matched that of multiple proviral DNA copies from infected blood cells sampled before treatment interruption. In addition, we found that these cells were not dormant but were generating unspliced RNA transcripts before treatment was interrupted. Identification of the HIV reservoir and determining its mechanisms for persistence may aid in the development of strategies toward a cure for HIV. (This study was presented in part at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23 to 26 2015.)


2017 ◽  
Vol 2 (3) ◽  
pp. 431 ◽  
Author(s):  
You Jeong Park ◽  
Behzad Etemad ◽  
Hayat Ahmed ◽  
Vivek Naranbhai ◽  
Evgenia Aga ◽  
...  

Identifying host determinants associated with HIV reservoir size and viral rebound timing after an analytic treatment interruption (ATI) is an important step in the search for an HIV functional cure. A pooled analysis of 103 participants from four AIDS Clinical Trials Group ATI studies to identify the association between HLA class I alleles with HIV reservoir size and viral rebound timing. Total HIV DNA and cell-associated HIV RNA (CA-RNA) were quantified in pre-ATI peripheral blood mononuclear cell samples, and residual plasma viremia was measured using the single-copy assay. HLA class I typing was performed and we generated an odds ratio (OR) of predicted HLA effect on HIV viremia control for each individual and compared this with time to viral rebound, and levels of HIV DNA and CA-RNA. There was no significant association between the HLA ORs and levels of HIV DNA or CA-RNA, but carriage of protective HLA-B alleles (lower OR scores) was associated with delayed viral rebound (P=0.02). Higher OR scores at the HLA-C locus were associated with longer duration of ART treatment (P=0.01) and this trend was also seen with the combined OR score (P=0.007). Individuals with protective HLA-B alleles had delayed viral rebound after treatment interruption that was not explained by differences in baseline reservoir size. The results indicate the vital role of cellular host immunity in preventing HIV rebound and the importance of taking into account the HLA status of study participants being evaluated in HIV cure trials.


Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 321-LB
Author(s):  
ANETA ALAMA ◽  
DOROTA PAWE?KA ◽  
ANETA MYSZCZYSZYN ◽  
MALGORZATA MALODOBRA-MAZUR

Sign in / Sign up

Export Citation Format

Share Document